Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (603392.SH) announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech, has been selected in the 2025 National Immunization Program Vaccine Tender for its bivalent human papillomavirus vaccine (E. coli strain). The centralized procurement, organized by the Chinese Center for Disease Control and Prevention, could potentially expand sales volume and market share of the included product if the company secures subsequent supply contracts. This inclusion is expected to enhance domestic market penetration and strengthen the company's brand influence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments